ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.74
-0.47%
US Tech 100
18,248.00
0.09%
S&P 500
5,320.15
-0.02%
US Dollar vs CAD
1.36677
0.20%
Bitcoin
69,507.98
-0.89%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Galapagos (GLPG)

  7. Galapagos (GLPG) News

GLPG

Galapagos (GLPG)

Galapagos
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:GLPG
DateTimeSourceHeadlineSymbolCompany
02/22/20243:01PMUK RegulatoryGalapagos announces full year 2023 results and outlook for 2024LSE:GLPGGalapagos
02/15/20243:01PMUK RegulatoryGalapagos presents at EBMT-EHA annual meeting 2024LSE:GLPGGalapagos
01/31/20243:01PMUK RegulatoryGalapagos completes transaction to transfer Jyseleca® business to AlfasigmaLSE:GLPGGalapagos
05/06/201512:31AMGlobeNewswireGalapagos listed 10 years on Euronext Amsterdam and BrusselsLSE:GLPGGalapagos
05/06/201512:31AMGlobeNewswireGalapagos announces launch of proposed global offeringLSE:GLPGGalapagos
05/01/201511:00AMGlobeNewswireBNP Paribas notify of 4.8% shareholding in GalapagosLSE:GLPGGalapagos
05/01/201511:00AMGlobeNewswireGalapagos creates new warrant planLSE:GLPGGalapagos
04/27/20153:00PMGlobeNewswireFilgotinib as monotherapy also hits primary endpoint in DARWIN 2 trialLSE:GLPGGalapagos
04/15/20154:00PMGlobeNewswireGalapagos files registration statement in the United States for a proposed global offeringLSE:GLPGGalapagos
04/14/20153:00PMGlobeNewswireGalapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in...LSE:GLPGGalapagos
03/27/20151:29PMGlobeNewswirePublication of Annual Report 2014 and invitation to the Annual Shareholders' Meeting to be held on 28 April 2015LSE:GLPGGalapagos
03/27/20151:30AMGlobeNewswireGalapagos raises €5.8 million through warrant exercises, Board and Executive Committee members investLSE:GLPGGalapagos
03/17/20151:31AMGlobeNewswireGalapagos regains rights to GLPG1690, announces end of alliance with JanssenLSE:GLPGGalapagos
03/06/201512:35AMGlobeNewswireGalapagos to be included in Amsterdam Midcap IndexLSE:GLPGGalapagos
03/06/201512:31AMGlobeNewswireGalapagos reports 2014 financial resultsLSE:GLPGGalapagos
02/23/201512:30AMGlobeNewswireGalapagos reports that the last patient in DARWIN 1 has completed 12 weeks of treatmentLSE:GLPGGalapagos
02/16/201512:30AMGlobeNewswireGalapagos reports positive Phase 1 results for GLPG1690LSE:GLPGGalapagos
02/11/201512:31AMGlobeNewswireGalapagos receives €1.6 million IWT grant for hepatitis B programLSE:GLPGGalapagos
02/09/201512:31AMGlobeNewswireBNP Paribas notify of 5.08% shareholding in GalapagosLSE:GLPGGalapagos
01/22/201512:31AMGlobeNewswireGalapagos receives €2.5 million IWT grant for antibiotic researchLSE:GLPGGalapagos
01/21/201511:56AMGlobeNewswireDelta Lloyd notify of 4.96% shareholding in GalapagosLSE:GLPGGalapagos
01/09/201512:30AMGlobeNewswireVicki Sato resigns from Galapagos BoardLSE:GLPGGalapagos
01/08/201512:30AMGlobeNewswireGalapagos starts Phase 2 trial with GLPG1205 in ulcerative colitis patientsLSE:GLPGGalapagos
12/19/201412:31AMGlobeNewswireGalapagos initiates first Phase 1 study in cystic fibrosis and will receive milestone payment from AbbVieLSE:GLPGGalapagos
12/16/201412:32AMGlobeNewswireGalapagos regains full rights to GPR84 inhibitor GLPG1205LSE:GLPGGalapagos
12/12/201412:31AMGlobeNewswireGalapagos selects second component of its investigational cystic fibrosis combination treatmentLSE:GLPGGalapagos
08/08/201412:30AMGlobeNewswireGalapagos cash position of €232 M provides solid basis for R&D pipeline investmentLSE:GLPGGalapagos
08/05/201412:31AMGlobeNewswireGalapagos receives milestone in osteoarthritis alliance with ServierLSE:GLPGGalapagos
07/25/201411:00AMGlobeNewswireGalapagos creates new warrant planLSE:GLPGGalapagos
07/23/201412:30AMGlobeNewswireMorphoSys and Galapagos Advance Joint Antibody Program in Inflammatory Diseases into Preclinical DevelopmentLSE:GLPGGalapagos
 Showing the most relevant articles for your search:LSE:GLPG

Your Recent History

USOTC
SRMX
Saddle Ranch Media (PK)
USOTC
QEDN
QED Connect (PK)
USOTC
CBIA
Canopus Biopharma (PK)
USOTC
IBGR
Nexus Energy Services (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
DPLS
DarkPulse (PK)
USOTC
ERHE
ERHC Energy (CE)
USOTC
WNFT
Worldwide NFT (CE)
USOTC
SONGD
Music Licensing (PK)
USOTC
GDVM
Global Developments (PK)
NASDAQ
TSLA
Tesla
NASDAQ
LWLG
Lightwave Logic
USOTC
PSRU
Valiant Eagle (PK)
USOTC
GNCP
GNCC Capital (CE)
USOTC
BIEL
Bioelectronics (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved